Please Wait.....
Report
Saudi Arabia Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-06-01 I 80 Pages I Allied Market Research
In a nation where diabetes is alarmingly prevalent, point-of-care glucose testing plays a pivotal role in managing the condition. The Saudi Arabia point-of-care glucose testing market is majorly driven by rise in incidence of diabetes in the country. Moreover, alarming increase in prevalence of both type-1 and type-2 diabetes acts as a prominent factor that augments the demand for glucose monitoring tools, thus contributing toward the growth of the point-of-care glucose testing market.Moreover, technological advancements in the field of glucose monitoring have revolutionized the way patients manage their conditions. The introduction of sophisticated lancing devices and blood glucose meters has not only made glucose testing more accessible but also more accurate.In addition, the inclination toward preventive care is another driving force of the Saudi Arabia point-of-care glucose testing market. Hospitals, clinics, and home care settings have embraced point-of-care glucose testing as a critical tool in early diagnosis and patient management. As a result, the market is witnessing a steady flow of investment and adoption.However, the cost associated with high-end glucose monitoring devices restrains the market growth. Although advanced technology has improved accuracy, it has pushed the prices upwards, making it a challenge for patients with limited financial resources to access these tools.Moreover, lack of awareness regarding diabetes and glucose testing among the general population limits the growth of the market.
On the contrary, the convenience and efficiency of at-home glucose testing are enticing more patients to take charge of their health. This shift serves as a potential opportunity for the market growth in the coming years.As the demand for accurate and non-invasive glucose monitoring solutions continues to rise, it will inevitably spur the growth of new, more user-friendly technologies, which is anticipated to propel the market growth.Government initiatives and regulations further pave the way for growth. With a commitment to improving healthcare infrastructure and patient outcomes, Saudi Arabia is likely to witness an increase in investments in this sector. This will create new avenues for market expansion.The Saudi Arabia point-of-care glucose testing market is segmented into product type, application, and end user. On the basis of product type, the market is fragmented into lancing devices & strips and blood glucose meters. Lancing devices and strips being popular for their ease of use and accessibility. Blood glucose meters, on the other hand, are favored for their precision. Depending on application, it is bifurcated into type-1 diabetes and type-2 diabetes. Type-1 diabetes patients often require more intensive monitoring, as their condition is insulin-dependent. In contrast, type-2 diabetes, while more common, may necessitate less frequent testing. This distinction underscores the importance of catering to the specific needs of each group. By end user, it is categorized into hospitals & clinics, home care settings, and others. Hospitals & clinics often provide immediate care, whereas home care settings offer long-term monitoring and patient empowerment.
The prominent players operating in the Saudi Arabia point-of-care glucose testing market are Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Nova Biomedical, Bionime, Sinocare, Medtronic, LifeScan, ACON Laboratories, Ypsomed Holding AGNew product development is a critical aspect, with manufacturers investing in R&D to introduce more user-friendly and cost-effective solutions.Consumer and end-user perceptions are heavily influenced by the ease of use, accuracy, and reliability of glucose testing devices. Patients seek tools that integrate seamlessly into their daily routines, minimizing disruption and discomfort. Healthcare providers, on the other hand, value devices that provide precise data to inform treatment decisions.The Porter's five forces analysis reveals a complex landscape of competitive rivalry, bargaining power of suppliers, bargaining power of buyers, threat of new entrants, and threat of substitute products.Competitive rivalry is intensified as more manufacturers enter the market, striving to capture a share of the growing demand for glucose testing tools. The diversity in product types and applications further amplifies competition.Suppliers of glucose monitoring devices may hold significant bargaining power, especially those producing cutting-edge technology. As demand surges, suppliers have the leverage to dictate terms and prices.
Buyers, predominantly hospitals and clinics, have some bargaining power due to the wide range of product options available. They can choose from various manufacturers, impacting prices and terms.The threat of new entrants is influenced by the barriers to entry, including regulatory requirements and the need for substantial research and development investments. However, the demand for innovative solutions continues to attract potential newcomers. The threat of substitute products primarily pertains to alternative glucose monitoring methods, such as continuous glucose monitoring (CGM) systems. The choice between traditional Point-of-Care testing and CGM systems depends on individual patient needs and preferences.A SWOT analysis further unveils the internal strengths and weaknesses and the external opportunities and threats in the Saudi Arabia point-of-care glucose testing market.Strengths include the market's adaptability and responsiveness to technological advancements. This agility ensures that patients have access to cutting-edge solutions for disease management.
Weaknesses revolve around the cost of advanced glucose monitoring devices and the need for better awareness among the population about the importance of regular testing.Opportunities are abundant, driven by the rising diabetes prevalence and the government's commitment to enhancing healthcare infrastructure. Innovations in product development and the growth of home care settings are key opportunities.Threats include the intense competition among manufacturers, as well as the threat of substitute products like CGM systems. Maintaining market share and relevance amidst these challenges is a critical consideration.In conclusion, as Saudi Arabia grapples with the growing burden of diabetes, the point-of-care glucose testing market continues to evolve, offering hope and progress in the quest for improved patient care and disease management.
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in Saudi Arabia point-of-care glucose testing market.
Assess and rank the top factors that are expected to affect the growth of Saudi Arabia point-of-care glucose testing market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Saudi Arabia point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Product Type
- Lancing Devices and Strips
- Blood-Glucose Meter
? Type
? Lifescan OneTouch Ultra and Lifescan OneTouch Verio
? Accu-Chek Aviva Plus and Accuchek
? Freestyle Lite and Freestyle Precission Neo
? Contour Next
? Others
By Application
- Type-1 Diabetes
- Type-2 Diabetes
By End User
- Hospitals and Clinics
- Home Care Settings
- Others
- Key Market Players
? Roche Diagnostics
? Abbott Laboratories
? Siemens Healthineers
? Nova Biomedical
? Bionime
? Sinocare
? Medtronic
? LifeScan
? ACON Laboratories
? Ypsomed Holding AG
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market Size and Forecast, By Product Type
4.2. Lancing Devices and Strips
4.3. Blood-Glucose Meter
CHAPTER 5: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Type-1 Diabetes
5.3. Type-2 Diabetes
CHAPTER 6: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market Size and Forecast, By End User
6.2. Hospitals and Clinics
6.3. Home Care Settings
6.4. Others
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Roche Diagnostics
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Abbott Laboratories
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Siemens Healthineers
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Nova Biomedical
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Bionime
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Sinocare
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Medtronic
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. LifeScan
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. ACON Laboratories
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Ypsomed Holding AG
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 04. ROCHE DIAGNOSTICS: KEY EXECUTIVES
TABLE 05. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 06. ROCHE DIAGNOSTICS: OPERATING SEGMENTS
TABLE 07. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 08. ROCHE DIAGNOSTICS: KEY STRATERGIES
TABLE 09. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 10. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 11. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 12. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 13. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 14. SIEMENS HEALTHINEERS: KEY EXECUTIVES
TABLE 15. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
TABLE 16. SIEMENS HEALTHINEERS: OPERATING SEGMENTS
TABLE 17. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 18. SIEMENS HEALTHINEERS: KEY STRATERGIES
TABLE 19. NOVA BIOMEDICAL: KEY EXECUTIVES
TABLE 20. NOVA BIOMEDICAL: COMPANY SNAPSHOT
TABLE 21. NOVA BIOMEDICAL: OPERATING SEGMENTS
TABLE 22. NOVA BIOMEDICAL: PRODUCT PORTFOLIO
TABLE 23. NOVA BIOMEDICAL: KEY STRATERGIES
TABLE 24. BIONIME: KEY EXECUTIVES
TABLE 25. BIONIME: COMPANY SNAPSHOT
TABLE 26. BIONIME: OPERATING SEGMENTS
TABLE 27. BIONIME: PRODUCT PORTFOLIO
TABLE 28. BIONIME: KEY STRATERGIES
TABLE 29. SINOCARE: KEY EXECUTIVES
TABLE 30. SINOCARE: COMPANY SNAPSHOT
TABLE 31. SINOCARE: OPERATING SEGMENTS
TABLE 32. SINOCARE: PRODUCT PORTFOLIO
TABLE 33. SINOCARE: KEY STRATERGIES
TABLE 34. MEDTRONIC: KEY EXECUTIVES
TABLE 35. MEDTRONIC: COMPANY SNAPSHOT
TABLE 36. MEDTRONIC: OPERATING SEGMENTS
TABLE 37. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 38. MEDTRONIC: KEY STRATERGIES
TABLE 39. LIFESCAN: KEY EXECUTIVES
TABLE 40. LIFESCAN: COMPANY SNAPSHOT
TABLE 41. LIFESCAN: OPERATING SEGMENTS
TABLE 42. LIFESCAN: PRODUCT PORTFOLIO
TABLE 43. LIFESCAN: KEY STRATERGIES
TABLE 44. ACON LABORATORIES: KEY EXECUTIVES
TABLE 45. ACON LABORATORIES: COMPANY SNAPSHOT
TABLE 46. ACON LABORATORIES: OPERATING SEGMENTS
TABLE 47. ACON LABORATORIES: PRODUCT PORTFOLIO
TABLE 48. ACON LABORATORIES: KEY STRATERGIES
TABLE 49. YPSOMED HOLDING AG: KEY EXECUTIVES
TABLE 50. YPSOMED HOLDING AG: COMPANY SNAPSHOT
TABLE 51. YPSOMED HOLDING AG: OPERATING SEGMENTS
TABLE 52. YPSOMED HOLDING AG: PRODUCT PORTFOLIO
TABLE 53. YPSOMED HOLDING AG: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 10. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
FIGURE 11. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. ROCHE DIAGNOSTICS: NET SALES, 2020-2022*($MILLION)
FIGURE 21. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. ABBOTT LABORATORIES: NET SALES, 2020-2022*($MILLION)
FIGURE 24. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. ABBOTT LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. SIEMENS HEALTHINEERS: NET SALES, 2020-2022*($MILLION)
FIGURE 27. SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. SIEMENS HEALTHINEERS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. NOVA BIOMEDICAL: NET SALES, 2020-2022*($MILLION)
FIGURE 30. NOVA BIOMEDICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. NOVA BIOMEDICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. BIONIME: NET SALES, 2020-2022*($MILLION)
FIGURE 33. BIONIME: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. BIONIME: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. SINOCARE: NET SALES, 2020-2022*($MILLION)
FIGURE 36. SINOCARE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. SINOCARE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. MEDTRONIC: NET SALES, 2020-2022*($MILLION)
FIGURE 39. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. MEDTRONIC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. LIFESCAN: NET SALES, 2020-2022*($MILLION)
FIGURE 42. LIFESCAN: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. LIFESCAN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. ACON LABORATORIES: NET SALES, 2020-2022*($MILLION)
FIGURE 45. ACON LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. ACON LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. YPSOMED HOLDING AG: NET SALES, 2020-2022*($MILLION)
FIGURE 48. YPSOMED HOLDING AG: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. YPSOMED HOLDING AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security